Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Heise

Showing results (131-140 of 150) with videos related to

Pageof 15
Sort By:
JAMA|January 25, 2017
Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical TrialMarcus Lind, William Polonsky, Irl B Hirsch, et al.
Diabetes, Obesity & Metabolism|November 17, 2020
The majority of people with type 1 diabetes and multiple daily insulin injections benefit from using continuous glucose monitoring: An analysis based on the GOLD randomized trial (GOLD-5)Arndís F Ólafsdóttir, Jan Bolinder, Tim Heise, et al.
The Journal of Clinical Endocrinology and Metabolism|May 25, 2024
Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal TestKieren J Mather, Andrea Mari, Tim Heise, et al.
Diabetes Care|March 1, 2023
Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 DiabetesTim Heise, J Hans DeVries, Shweta Urva, et al.
Diabetes Care|July 10, 2020
The Association Between HbA<sub>1c</sub> and Time in Hypoglycemia During CGM and Self-Monitoring of Blood Glucose in People With Type 1 Diabetes and Multiple Daily Insulin Injections: A Randomized Clinical Trial (GOLD-4)Shilan Seyed Ahmadi, Klara Westman, Aldina Pivodic, et al.
Lancet (London, England)|June 28, 2018
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a studyPhilip Ambery, Victoria E Parker, Michael Stumvoll, et al.
Hypertension (Dallas, Tex. : 1979)|November 29, 2017
Effect of Sacubitril/Valsartan on Exercise-Induced Lipid Metabolism in Patients With Obesity and HypertensionStefan Engeli, Rudi Stinkens, Tim Heise, et al.
British Journal of Clinical Pharmacology|May 1, 2024
The effect of AZD9567 vs. prednisolone on glycaemic control in patients with type 2 diabetes mellitus: Results from a phase 2a clinical trialPhilip Ambery, Grzegorz Zajac, Joachim Almquist, et al.
The Journal of Clinical Endocrinology and Metabolism|October 15, 2019
Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon AgonistVictoria E R Parker, Darren Robertson, Tao Wang, et al.
Primary Care Diabetes|November 13, 2020
Integrated personalized diabetes management goes Europe: A multi-disciplinary approach to innovating type 2 diabetes care in EuropeAllan Jones, Jakob Eyvind Bardram, Per Bækgaard, et al.
Pageof 15

Showing results (131-140 of 150) with videos related to

Sort By:
Pageof 15
JAMA|January 25, 2017
Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical TrialMarcus Lind, William Polonsky, Irl B Hirsch, et al.
Diabetes, Obesity & Metabolism|November 17, 2020
The majority of people with type 1 diabetes and multiple daily insulin injections benefit from using continuous glucose monitoring: An analysis based on the GOLD randomized trial (GOLD-5)Arndís F Ólafsdóttir, Jan Bolinder, Tim Heise, et al.
The Journal of Clinical Endocrinology and Metabolism|May 25, 2024
Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal TestKieren J Mather, Andrea Mari, Tim Heise, et al.
Diabetes Care|March 1, 2023
Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 DiabetesTim Heise, J Hans DeVries, Shweta Urva, et al.
Diabetes Care|July 10, 2020
The Association Between HbA<sub>1c</sub> and Time in Hypoglycemia During CGM and Self-Monitoring of Blood Glucose in People With Type 1 Diabetes and Multiple Daily Insulin Injections: A Randomized Clinical Trial (GOLD-4)Shilan Seyed Ahmadi, Klara Westman, Aldina Pivodic, et al.
Lancet (London, England)|June 28, 2018
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a studyPhilip Ambery, Victoria E Parker, Michael Stumvoll, et al.
Hypertension (Dallas, Tex. : 1979)|November 29, 2017
Effect of Sacubitril/Valsartan on Exercise-Induced Lipid Metabolism in Patients With Obesity and HypertensionStefan Engeli, Rudi Stinkens, Tim Heise, et al.
British Journal of Clinical Pharmacology|May 1, 2024
The effect of AZD9567 vs. prednisolone on glycaemic control in patients with type 2 diabetes mellitus: Results from a phase 2a clinical trialPhilip Ambery, Grzegorz Zajac, Joachim Almquist, et al.
The Journal of Clinical Endocrinology and Metabolism|October 15, 2019
Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon AgonistVictoria E R Parker, Darren Robertson, Tao Wang, et al.
Primary Care Diabetes|November 13, 2020
Integrated personalized diabetes management goes Europe: A multi-disciplinary approach to innovating type 2 diabetes care in EuropeAllan Jones, Jakob Eyvind Bardram, Per Bækgaard, et al.
Pageof 15